Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86
   PubMed Web of Science ®Google Scholar
• Okines A, Verheij M, Allum W, Cunningham D, Cervantes, A. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:50–4
   PubMed Web of Science ®Google Scholar
• Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005;12:347–53
   PubMed Web of Science ®Google Scholar
• Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: Natural history and outcome of 291 patients. Ann Surg Oncol 2010;17:3173–80
   PubMed Web of Science ®Google Scholar
• Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, et al. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol 2014;21:1448–55
   PubMed Web of Science ®Google Scholar
• Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009;250:878–87
   PubMed Web of Science ®Google Scholar
• Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003;27:153–8
   PubMed Web of Science ®Google Scholar
• Marutsuka T, Shimada S, Shiomori K, Hayashi N, Yagi Y, Yamane T, Ogawa M. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: An ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res 2003;9:678–85
   PubMed Web of Science ®Google Scholar
• Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Different patterns of recurrence in gastric cancer depending on Lauren's histological type: Longitudinal study. World J Surg 2002;26:1160–5
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol 2010;36:1131–8
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol, 2002;20:1996–2004
   PubMed Web of Science ®Google Scholar
• Roviello F, Caruso S, Marrelli D, Pedrazzani C, Neri A, De Stefano A, Pinto E. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: State of the art and future developments. Surg Oncol 2011;20: e38–54
   Google Scholar
• Montori G, Coccolini F, Ceresoli M, Catena F, Colaianni N, Poletti E, Ansaloni L The treatment of peritoneal carcinomatosis in advanced gastric cancer: State of the art. Int J Surg Oncol 2014;2014:912418
   PubMedGoogle Scholar
• Roviello F, Marrelli D, Neri A, Cerretani D, de Manzoni G, Pedrazzani C, et al. Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): Postoperative outcome and risk factors for morbidity. World J Surg 2006;30:2033–40
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of post-operative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529–34
   PubMed Web of Science ®Google Scholar
• Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000;87:353–7
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly F, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients. Cancer 2010;1116:5608–18
   Web of Science ®Google Scholar
• Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370–5
   PubMed Web of Science ®Google Scholar
• Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003;90:1113–19
   PubMed Web of Science ®Google Scholar
• Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol.2007;14:2702–13
   PubMed Web of Science ®Google Scholar
• Mi DH, Li Z, Yang KH, Cao N, Lethaby A, Tian JH, et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: A systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia 2013;29:156–67
   PubMed Web of Science ®Google Scholar
• Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: A meta-analysis of the randomized controlled trials. BMC Cancer 2012;12:526
   PubMed Web of Science ®Google Scholar
• Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 2014;40:12–26
   PubMed Web of Science ®Google Scholar
• Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004;10:2727–30
   PubMed Web of Science ®Google Scholar
• Weisberger AS, Levine B, Storaasli JP: Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955;159:1704–7
   PubMed Web of Science ®Google Scholar
• Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256–60
   PubMed Web of Science ®Google Scholar
• Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014;50:332–40
   PubMed Web of Science ®Google Scholar
• Chua TC, Saxena A, Schellekens JF, Liauw W, Yan TD, Fransi S, et al. Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: Towards a new perspective of this treatment. Ann Surg 2010;251:101–6
   PubMed Web of Science ®Google Scholar
• Gray NM, Hall SJ, Browne S, Macleod U, Mitchell E, Lee AJ, et al. Modifiable and fixed factors predicting quality of life in people with colorectal cancer. Br J Cancer 2011;104:1697–703
   PubMed Web of Science ®Google Scholar
• Piso P, Glockzin G, von Breitenbuch P, Popp FC, Dahlke MH, Schlitt HJ, Nissan A. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. J Surg Oncol. 2009; 100: 317–320
   PubMed Web of Science ®Google Scholar
• McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, Stewart JH, Levine EA. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2007;14:1105–13
   PubMed Web of Science ®Google Scholar
• Tsilimparis N, Bockelmann C, Raue W, Menenakos C, Perez S, Rau B, Hartmann J. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Is it worth the risk? Ann Surg Oncol 2013;20:226–32
   PubMed Web of Science ®Google Scholar
• Zenasni F, Botella M, Elias D, Dauchy S, Boige V, Malka D, et al. The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: A cross-sectional study. Support Care Cancer 2009;17:1255–61
   PubMed Web of Science ®Google Scholar
• Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol 2013;107:566–73
   PubMed Web of Science ®Google Scholar
• Bhagwandin S, Naffouje S, Salti G. Utility of chemoresponse assay in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2015;22:2573–7
   PubMed Web of Science ®Google Scholar
• Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364–7
   PubMed Web of Science ®Google Scholar
• Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim SH, et al. A phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 2007;37:930–5
   PubMed Web of Science ®Google Scholar
• Sangisetty SL, Miner TJ. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 2012;4:87–95
   PubMedGoogle Scholar
• Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 2014;21:1474–9
   PubMed Web of Science ®Google Scholar
• Ozden S, Ozgen Z, Ozyurt H, Gemici C, Yaprak G, Tepetam H, Mayadagli A. Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. World J Gastroenterol 2015;21:1222–33
   PubMed Web of Science ®Google Scholar
• Piotrowski T, Jodda A. How to compare treatment plans? Personalized perspective. Rep Pract Oncol Radiother 2014;20:77–8
   PubMedGoogle Scholar
• Voyant C, Julian D, Roustit R, Biffi K, Lantieri C. Biological effects and equivalent doses in radiotherapy: A software solution. Rep Pract Oncol Radiother 2014;19:47–55
   PubMedGoogle Scholar
• Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, et al. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer 2015;18:833–42
   PubMed Web of Science ®Google Scholar
• Burke EC, Karpeh MS, Conlon KC, Brennan MF. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 1997;225:262–7
   PubMed Web of Science ®Google Scholar
• Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing curative resection. Ann Surg Oncol 2005;12:347–53
   PubMed Web of Science ®Google Scholar
• Ohashi N, Nakanishi H, Kodera Y, Ito S, Mochizuki Y, Koike M, et al. Intraoperative quantitative detection of CEA mRNA in the peritoneal lavage of gastric cancer patients with transcription reverse-transcription concerted (TRC) method. A comparative study with real-time quantitative RT-PCR. Anticancer Res 2007;27:2769–77
   PubMed Web of Science ®Google Scholar
• Kagawa S, Shigeyasu K, Ishida M, Watanabe M, Tazawa H, Nagasaka T, et al. Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients. World J Gastroenterol 2014;20:17796–803
   PubMed Web of Science ®Google Scholar
• Polom W, Markuszewski M, Rho YS, Matuszewski M. Use of invisible near infrared light fluorescence with indocyanine green and methylene blue in urology. Part 2. Cent Eur J Urol 2014;67:310–13
   PubMedGoogle Scholar
• de Boer E, Harlaar NJ, Taruttis A, Nagengast WB, Rosenthal EL, Ntziachristos V, van Dam GM. Optical innovations in surgery. Br J Surg 2015;102:e56–72
   PubMed Web of Science ®Google Scholar
• Polom W, Markuszewski M, Rho YS, Matuszewski M. Usage of invisible near infrared light (NIR) fluorescence with indocyanine green (ICG) and methylene blue (MB) in urological oncology. Part 1. Cent Eur J Urol 2014;67:142–8
   PubMedGoogle Scholar
• Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Löwik CW, et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol 2011;104:323–32
   PubMed Web of Science ®Google Scholar
• Murawa D, Polom K, Rho YS, Murawa P. Developments in near-infrared-guided hepatobiliary, pancreatic and other upper gastrointestinal surgery. Contrast Media Mol Imaging 2013;8:211–19
   PubMed Web of Science ®Google Scholar
• Polom K, Murawa D, Nowaczyk P, Rho YS, Murawa P. Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green – human serum albumin in comparison with gamma emitting radioactive colloid tracer. Eur J Surg Oncol 2012;38:137–42
   PubMed Web of Science ®Google Scholar
• Mitsumori N, Nimura H, Takahashi N, Kawamura M, Aoki H, Shida A, et al. Sentinel lymph node navigation surgery for early stage gastric cancer. World J Gastroenterol 2014;20:5685–93
   PubMed Web of Science ®Google Scholar
• Polom K, Murawa D, Rho YS, Spychala A, Murawa P. Skin melanoma sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin. Br J Dermatol 2012;166:682–3
   PubMed Web of Science ®Google Scholar
• Nakano T, Sakurai T, Maruyama S, Ozawa Y, Kamei T, Miyata G, Ohuchi N. Indocyanine green fluorescence and three-dimensional imaging of right gastroepiploic artery in gastric tube cancer. World J Gastroenterol 2015;21:369–72
   PubMed Web of Science ®Google Scholar
• van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: First in-human results. Nat Med 2011;17:1315–19
   PubMed Web of Science ®Google Scholar
• van Oosten M, Crane LM, Bart J, van Leeuwen FW, van Dam GM. Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using target selection criteria (TASC): A novel target identification tool. Transl Oncol 2011;4:71–82
   PubMed Web of Science ®Google Scholar
• Ito A, Ito Y, Matsushima S, Tsuchida D, Ogasawara M, Hasegawa J, et al. New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice. Gastric Cancer 2014;17:497–507
   PubMed Web of Science ®Google Scholar
• Hoshino I, Maruyama T, Fujito H, Tamura Y, Suganami A, Hayashi H, et al. Detection of peritoneal dissemination with near-infrared fluorescence laparoscopic imaging using a liposomal formulation of a synthesized indocyanine green liposomal derivative. Anticancer Res 2015;35:1353–9
   PubMed Web of Science ®Google Scholar
• Murayama Y, Ichikawa D, Koizumi N, Komatsu S, Shiozaki A, Kuriu Y, et al. Staging fluorescence laparoscopy for gastric cancer by using 5-aminolevulinic acid. Anticancer Res 2012;32:5421–7
   PubMed Web of Science ®Google Scholar
• Kishi K, Fujiwara Y, Yano M, Motoori M, Sugimura K, Ohue M, et al. Diagnostic laparoscopy with 5-aminolevulinic-acid-mediated photodynamic diagnosis enhances the detection of peritoneal micrometastases in advanced gastric cancer. Oncology 2014;87:257–65
   PubMed Web of Science ®Google Scholar
• Kitayama J. Intraperitoneal chemotherapy against peritoneal carcinomatosis: Current status and future perspective. Surg Oncol 2014;23:99–106
   PubMed Web of Science ®Google Scholar
• Rettenmaier MA, Mendivil AA, Abaid LN, Brown JV III, Wilcox AM, Goldstein BH. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma. Int J Hyperthermia 2015;31:8–14
   PubMed Web of Science ®Google Scholar
• Heiss M, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III Trial. Int J Cancer 2010;127:2209–21
   PubMed Web of Science ®Google Scholar
• Nagayama A, Hayashida T, Jinno H, Takahashi M, Seki T, Matsumoto A, et al. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: A network meta-analysis. J Natl Cancer Inst 2014;106:dju203
   PubMedGoogle Scholar
• Jácome AA, Sankarankutty AK, Dos Santos JS. Adjuvant therapy for gastric cancer: What have we learned since INT0116? World J Gastroenterol 2015;21:3850–9
   PubMed Web of Science ®Google Scholar
• Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: A subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer 2012;15(3):313–22
   PubMed Web of Science ®Google Scholar
• Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011;104:1372–6. Erratum: Br J Cancer 2011;104:1929
   PubMed Web of Science ®Google Scholar
• Berretta M, Fisichella R, Borsatti E, Lleshi A, Ioffredo S, Meneguzzo N, et al. Feasibility of intraperitoneal trastuzumab treatment in a patient with peritoneal carcinomatosis from gastric cancer. Eur Rev Med Pharmacol Sci 2014;18:689–92
   PubMed Web of Science ®Google Scholar
• Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, et al. Clinicopathological factors associated with HER2 status in gastric cancer: Results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer 2015;PMID:26265390
   Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687–97
   PubMed Web of Science ®Google Scholar
• de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: A step forward. World J Gastroenterol 2013;19:6165–9
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis. Ann Oncol 2012;23:2656–62
   PubMed Web of Science ®Google Scholar
• Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, Roviello F. Multimodal treatment of non-cardia gastric cancer in the west: Where are we going? World J Gastroenterol 2015;21(26):7954–69
   PubMed Web of Science ®Google Scholar
• Cihoric N, Tsikkinis A, van Rhoon G, Crezee H, Aebersold DM, Bodis S, et al. Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. Int J Hyperthermia 2015;31:609–14
   PubMed Web of Science ®Google Scholar
• Stamou K, Tsamis D, Pallas N, Samanta E, Courcoutsakis N, Prassopoulos P, et al. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature. Int J Hyperthermia 2015:1–7PMID:26382910
   Google Scholar